Analysis of clinical characteristics of Chinese and western medicine inpatients with advanced gastric cancer receiving second-line and follow-up treatment
|更新时间:2023-06-16
|
Analysis of clinical characteristics of Chinese and western medicine inpatients with advanced gastric cancer receiving second-line and follow-up treatment
Beijing Journal of Traditional Chinese MedicineVol. 42, Issue 3, Pages: 333-337(2023)
WU Chao-xu,HOU Li,LI Xiao,et al.Analysis of clinical characteristics of Chinese and western medicine inpatients with advanced gastric cancer receiving second-line and follow-up treatment[J]. Beijing Journal of Traditional Chinese Medicine,2023,42(03):333-337.
WU Chao-xu,HOU Li,LI Xiao,et al.Analysis of clinical characteristics of Chinese and western medicine inpatients with advanced gastric cancer receiving second-line and follow-up treatment[J]. Beijing Journal of Traditional Chinese Medicine,2023,42(03):333-337. DOI: 10.16025/j.1674-1307.2023.03.027.
Analysis of clinical characteristics of Chinese and western medicine inpatients with advanced gastric cancer receiving second-line and follow-up treatment
Objective,2,To investigate the clinical characteristics of Chinese medicine and western medicine in 45 patients with advanced gastric cancer who received second-line and follow-up treatment based on the clinical data of these patients.,Methods,2,Patients with advanced gastric cancer who met the criteria for inclusion in the subject were divided into first-line treatment,second-line treatment and follow-up treatment according to the treatment methods. Through the comparison between groups and literature research, the clinical characteristics of Chinese and western medicine in patients with second-line and follow-up treatment were summarized.,Results,2,The male-to-female ratio of 45 patients with advanced gastric cancer who received second-line and subsequent treatments was about 3∶1, the average age was (57.53±12.96) years, the average BMI was (21.51±3.89) kg/m,2,,and the average hemoglobin was(111.58±17.82) g/L,serum albumin is(38.78±5.52) g/L, KPS score was concentrated at 80 points and above, and the degree of differentiation was mainly poorly differentiated. The primary tumor was mostly in the proximal stomach, and the distant metastasis was the most common single organ metastasis, there was no statistically significant difference compared to the first-line treatment patients(,P,>,0.05); while adenocarcinoma accounted for 95.56%, and the average survival time was(440.80±177.42) days, which was significantly higher than that of the first-line treatment patients(,P,<,0.05). The TCM evidence elements showed the characteristics of pathological combinations of spleen,liver and spleen,and spleen and kidney, and their corresponding pathological combinations were Qi deficiency with phlegm-dampness,Qi deficiency,Qi stagnation with phlegm-dampness, and Qi deficiency with Yin deficiency.,Conclusion,2,The pathological sites of 45 patients with advanced gastric cancer receiving second-line and follow-up treatment were mainly spleen, liver and kidney in TCM, and the pathological elements showed a combination of deficiency and excess, so it is advisable to use the treatment method of supporting the anti-pathogenic Qi and eliminating the pathogenic factors in a reasonable way. Compared with the first-line treatment patients, the western medicine characteristics of the second-line and follow-up treatment patients are mainly adenocarcinoma,but signet ring cell carcinoma is rare.
TAKASHIMA A, BOKU N, KATO K, et al. Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912[J]. Gastric Cancer, 2014,17(3):522-528.
HSU C, SHEN YC, CHENG CC, et al. Geographic difference in safety and efficacy of systemicchemotherapy for advanced gastric or gastroesophagealcarcinoma: a meta-analysis and meta-regression[J]. Gastric Cancer, 2012,15(3):265-280.
FANOTTO V, CORDIO S, PASQUINI G, et al. Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world[J]. Gastric Cancer, 2017,20(5):825-833.
LEE JH, PARK B, JOO J, et al. Body mass index and mortality in patients with gastric cancer: a large cohort study[J]. Gastric Cancer, 2018,21(6):913-924.
ZHANG C, LIU R, ZHANG WH, et al. Difference between signet ring cell gastric cancers and non-signet ring cell gastric cancers: a systematic review and meta-analysis[J]. Front Oncol, 2021,11:618477.